Vascular smooth muscle cell peroxisome proliferator-activated receptor-γ mediates pioglitazone-reduced vascular lesion formation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 2, 2011, Pages 352-359

  Hamblin, Milton ^a   Chang, Lin ^a   Zhang, Hengmin ^a   Yang, Kun ^a   Zhang, Jifeng ^a   Chen, Y Eugene ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

transgenic models; transplantation; vascular biology; vascular muscle

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY; CAROTID ARTERY; CELL ADHESION; CONTROLLED STUDY; DIET; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; KNOCKOUT MOUSE; MICROSCOPY; MOUSE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRANSPLANTATION; VASCULAR LESION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ARTERITIS; CAROTID ARTERIES; CELL ADHESION; MICE; MICE, INBRED CBA; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, ANIMAL; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; PPAR GAMMA; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; TRANSPLANTATION, HOMOLOGOUS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 79551471791     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.110.219006     Document Type: Article

References (42)

1. Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the cardiovascular system. Antioxid Redox Signal. 2009;11:1415-1452.
2. Hamblin M, Chang L, Zhang J, Chen YE. The role of peroxisome proliferator-activated receptor y in blood pressure regulation. Curr Hypertens Rep. 2009;11:239-245.
3. Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-y both induce cardiac hypertrophy in mice. Circ Res. 2005;97:372-379.
4. Ding G, Fu M, Qin Q, Lewis W, Kim HW, Fukai T, Bacanamwo M, Chen YE, Schneider MD, Mangelsdorf DJ, Evans RM, Yang Q. Cardiac peroxisome proliferator-activated receptor y is essential in protecting cardiomyocytes from oxidative damage. Cardiovasc Res. 2007;76:269-279.
5. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPAR y-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161-171.
6. Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF. Conditional knockout of macrophage PPARy increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25: 1647-1653.
7. Villacorta L, Schopfer FJ, Zhang J, Freeman BA, Chen YE. PPARy and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond). 2009;116:205-218.
8. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
9. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-y is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
10. Jiang C, Ting AT, Seed B. PPAR-y agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
11. Wang N, VernaL, Chen NG, Chen J, LiH, Forman BM, Stemerman MB. Constitutive activation of peroxisome proliferator-activated receptory suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem. 2002;277:34176-34181.
12. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, Demer LL. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol. 1999;19:2094-2104.
13. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood. 1994;84:2068-2101.
14. Tanaka H, Sukhova GK, Swanson SJ, Cybulsky MI, Schoen FJ, Libby P. Endothelial and smooth muscle cells express leukocyte adhesion molecules heterogeneously during acute rejection of rabbit cardiac allografts. Am J Pathol. 1994;144:938-951.
15. Belperio JA, Ardehali A. Chemokines and transplant vasculopathy. Circ Res. 2008;103:454-466.
16. Schmauss D, Weis M. Cardiac allograft vasculopathy: recent developments. Circulation. 2008;117:2131-2141.
17. Kosuge H, Haraguchi G, Koga N, Maejima Y, Suzuki J, Isobe M. Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation. 2006;113:2613-2622.
18. Chang L, Villacorta L, Zhang J, Garcia-Barrio MT, Yang K, Hamblin M, Whitesall SE, D'Alecy LG, Chen YE. Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-y deletion leads to hypotension. Circulation. 2009;119:2161-2169.
19. Hillebrands JL, Klatter FA, Rozing J. Origin of vascular smooth muscle cells and the role of circulating stem cells in transplant arteriosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:380-387.
20. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-KB and cytokine-inducible enhancers. Faseb J. 1995;9:899-909.
21. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-KB activity. Annu Rev Immunol. 2000;18:621-663.
22. Lim S, Jin CJ, Kim M, Chung SS, Park HS, Lee IK, Lee CT, Cho YM, Lee HK, Park KS. PPARy gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol. 2006; 26:808-813.
23. Meredith D, Panchatcharam M, Miriyala S, Tsai YS, Morris AJ, Maeda N, Stouffer GA, Smyth SS. Dominant-negative loss of PPARy function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler Thromb Vasc Biol. 2009;29: 465-471.
24. Semple RK, Meirhaeghe A, Vidal-Puig AJ, Schwabe JW, Wiggins D, Gibbons GF, Gurnell M, Chatterjee VK, O'Rahilly S. A dominant negative human peroxisome proliferator-activated receptor (PPAR) a is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms. Endocrinology. 2005;146:1871-1882.
25. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S. Dominant negative mutations in human PPARy associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999;402:880-883.
26. Agostini M, Gurnell M, Savage DB, Wood EM, Smith AG, Rajanayagam O, Garnes KT, Levinson SH, Xu HE, Schwabe JW, Willson TM, O'Rahilly S, Chatterjee VK. Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor y. Endocrinology. 2004;145: 1527-1538.
27. Mitchell RN, Libby P. Vascular remodeling in transplant vasculopathy. Circ Res. 2007;100:967-978.
28. Weis M, von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation. 1997;96:2069-2077.
29. Ardehali A, Laks H, Drinkwater DC, Ziv E, Drake TA. Vascular cell adhesion molecule-1 is induced on vascular endothelia and medial smooth muscle cells in experimental cardiac allograft vasculopathy. Circulation. 1995;92:450-456.
30. Dietrich H, Hu Y, Zou Y, Dirnhofer S, Kleindienst R, Wick G, Xu Q. Mouse model of transplant arteriosclerosis: role of intercellular adhesion molecule-1. Arterioscler Thromb Vasc Biol. 2000;20:343-352.
31. Muller WA. Mechanisms of transendothelial migration of leukocytes. Circ Res. 2009;105:223-230.
32. Carman CV, Springer TA. A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J Cell Biol. 2004;167:377-388.
33. Couffinhal T, Duplaa C, Moreau C, Lamaziere JM, Bonnet J. Regulation of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in human vascular smooth muscle cells. Circ Res. 1994;74: 225-234.
34. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D, McCarty J, Ferguson M, Hudkins K, Benjamin CD, et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. Implications for the mode of progression of advanced coronary atherosclerosis. J Clin Invest. 1993;92:945-951.
35. Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IKBCK expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-α activators. J Biol Chem. 2000;275:36703-36707.
36. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-y. Nature. 2005;437:759-763.
37. Girnun GD, Domann FE, Moore SA, Robbins ME. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol. 2002;16: 2793-2801.
38. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-KB transcription factor and HIV-1. EMBO J. 1991;10:2247-2258.
39. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B. Activation of proliferator-activated receptors a and y induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273:25573-25580.
40. Warner SJ, Libby P. Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol. 1989;142:100-109.
41. Arbustini E, Grasso M, Diegoli M, Bramerio M, Foglieni AS, Albertario M, Martinelli L, Gavazzi A, Goggi C, Campana C, et al. Expression of tumor necrosis factor in human acute cardiac rejection. An immunohistochemical and immunoblotting study. Am J Pathol. 1991;139:709-715.
42. Imagawa DK, Millis JM, Seu P, Olthoff KM, Hart J, Wasef E, Dempsey RA, Stephens S, Busuttil RW. The role of tumor necrosis factor in allograft rejection. III. Evidence that anti-TNF antibody therapy prolongs allograft survival in rats with acute rejection. Transplantation. 1991;51: 57-62.